Osteoarthritis Flashcards

1
Q

Differential of knee pain

When is urgent referral required

A

Inflammatory

  • RA
  • Gout
  • Pseudogout (calcium pyrophosphate crystal deposition)
  • Spondyloarthritis

Infection

  • Septic arthritis
  • Osteomyelitis

Degenerative

  • Osteoarthritis

Soft tissue rheumatism

  • Tendonitis
  • Bursitis

Trauma

  • Fractures
  • Dislocation
  • Ligamentous injury
  • Patella problems

Tumors

Urgent referral: Red flags for Infection, trauma, malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What lab investigations are needed to differentiate gout VS RA vs septic arthritis vs pseudogout

A
  • Haematologic tests
  • Erythrocyte sedimentation rate (ESR)
  • C-reactive protein
  • Rheumatoid factor
  • Anticitrullinated protein antibody (ACPA/anti-CCP)
  • Joint aspiration (crystals - gout, WBC - septic)
  • X-ray / MRI (imaging to see extent of damage, may not see in early stages, however can be used to evaluate progression/tx outcomes)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is OA?

A

Degenerative disease (with synovial inflammation) of bone and joint cartilage

more than just ‘wear and tear’
progressive and irreversible loss of cartilage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Prevalence of OA

A

Increases with age

  • <50y: men > women (could be sports related)
  • > 70y: women > men (esp OA in hands)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Risk factors for OA

A
  • Genetic predisposition (e.g., mutation in collagen type in cartilage)
  • Anatomic factors (anatomical defects - e.g., bow-legged, valgus alignment, knocked-knee)
  • Joint injury (result in inflammation => cytokines have pro-catabolic and reduced anabolic activity, result in cartilage breakdown)
  • Obesity (incr load on weight-bearing joints)
  • Aging (changes in ECM: thinning, dcr hydration, incr brittleness, chondrocalcinosis)
  • Gender
  • Occupation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pathophysiology of OA

Compensatory response

A

1. Cartilage degradation

  • Articular cartilage damage
  • Chondrocyte repair (maintain ECM + produce cartilage matrix: type II collagen + proteoglycans)
  • Chondrocyte undergo phenotypic switch, produce type I collagen which causes weakening and breakdown of the matrix
  • Subchondral bone release vasoactive peptides and matrix metalloproteinases that break down collagen, resulting in cartilage loss and apoptosis of chondrocytes

2. Synovial inflammation

  • Weakening and degradation of collagen matrix results in formation of fibrillation in cartilage and cartilage ‘shards’
  • These shards cause inflammatory and pathologic changes in the joint capsule and synovium
  • Lymphocytes and macrophages recruited by synovial membrane to remove debris, produce pro-inflammatory cytokines, causing synovitis
  • Effusion (swelling of the knees)
  • Synovial thickening (narrowing of joint space)

3. Bone remodeling and osteophyte formation

  • Subchondral bones are exposed and rub against each other
  • Sclerosis: thickening of the subchondral bone => narrowing of joint space
  • Osteophytes: bone spurs, tiny protrusions of bone => causes widening of joints, intended to stabilize the joint in response to a normal mechanical loads
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Clinical Presentation of OA

A
  • Pain
  • Swelling (from joint effusion)
  • Erythematous and Warm
  • Morning stiffness <30min
  • Limited joint movement
  • Functional limitation/instability
  • Asymmetrical polyarthritis (typically weight bearing joints): hand, knee, hip, cervical/spine, finger (DIP, CMC)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pain in OA arises from:

A
  • Activation of nociceptive nerve endings within the joint by mechanical and chemical irritants
  • Distension of synovial capsule from increase joint fluid, microfracture, periosteal irritation, or damage to ligament, synovium or meniscus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

OA Pain characteristics:

A
  • Insidious onset => slow progression over years
  • Worse with joint use, relieved by rest

Usual presentation:

  • Stiff in morning
  • Gets better after walking for a bit
  • Then worsens again with joint use
  • Worse at the end of the day
  • Pain is most severe over joint line
  • Knees: worse going down stairs rather than going up
  • NO nocturnal pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pain in OA may be associated with:

A
  • Anxiety
  • Depression
  • Sleep disturbances
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

3 progressive stages of OA severity:

A

Stage 1:

  • Predictable sharp pain with mechanical insult, limits high-impact activities and modest effect on function

Stage 2:

  • Pain becomes more constant, with unpredictable episodes of stiffness => daily activity start to be affected

Stage 3:

  • Constant dull/aching pain punctuated by episodes of often unpredictable intense, exhausting pain => severe limitations in functions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

History taking for suspected OA:

A
  • Pain (deep, aching character; occurs on motion)
  • Morning stiffness <30min (resolves with motion, recurs with rest)
  • Impacts ADL negatively
  • Instability of weight-bearing joints
  • Symptoms related to weather
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Physical exam for suspected OA:

A
  • Asymmetric monoarticular or oligoarticular
  • Crepitus on motion
  • Reduced range of motion
  • Transient joint effusion
  • Palpable warmth
  • Bone tenderness
  • Bone enlargement (e.g., deformities on fingers - Heberden’s/Bouchard’s node; distal)
  • Muscle wasting/atrophy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Radiographic findings for suspected OA:

A
  • Joint space narrowing
  • Marginal osteophytes
  • Subchondral bone sclerosis
  • Abnormal alignment of joint

Note: typically only can see in advanced disease; not routinely done

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Laboratory findings for suspected OA:

A

ESR <20mm/h (inflammatory marker)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

[Diagnosis of OA]

Clinical diagnosis made without imaging in:

(May be diagnosed without radiography/lab investigations in presence of typical S&S in at-risk age group)

A

Based on NICE:

  • >=45y
  • Activity-related joint pain (one or few joints)
  • Morning stiffness =<30min or no morning stiffness

RECALL clinical presentation:

  • Pain
  • Swelling (from joint effusion)
  • Erythematous and Warm
  • Morning stiffness <30min
  • Limited joint movement
  • Functional limitation/instability
  • Asymmetrical polyarthritis (typically weight bearing joints): hand, knee, hip, cervical/spine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

[Diagnosis of OA]

Additional testing (REFER) should be considered for:

These people may require additional imaging for diagnosis

A
  1. Younger individuals
  2. Presence of atypical symptoms and signs that suggests alternative/additional diagnosis
  • History of recent trauma
  • Rapidly worsening symptoms or deformity (e.g., enlarged joints due to osteophytes, Heberden’s/Bouchard’s nodes on fingers)
  • Concerns of infection or malignancy (e.g., unusual site of involvement such as the wrist, marked pain at rest, unintended weight loss or constitutional symptoms such as fever, anorexia, malaise, headache, myalgia)
18
Q

Goals of treatment for OA:

A
  • Relieve pain and inflammation if any (via pharmaco)
  • Improve/preserve range of motion and joint function (via non-pharmaco)
  • Improve QoL
19
Q

OA Treatment overview:

Strongly recommended non-pharm includes

A
  • Exercise
  • Self-efficacy and self-management programs
  • Weight loss
  • Tai Chi
  • Knee brace (knee)
  • Carpometacarpal (CMC) split/orthosis (finger)
20
Q

OA Treatment overview:

Conditionally recommended non-pharm includes

A
  • Heat, therapeutic cooling
  • CBT
  • Acupuncture
  • Balance training, yoga
21
Q

OA Treatment overview:

Strongly against and conditionally against the following non-pharm

A

Strongly against:

  • TENS - transcutaneous electrical nerve stimulation

Conditionally against

  • Massage therapy
  • Modified shoes
22
Q

OA Treatment overview:

Strongly recommended pharm includes:

A
  • Topical NSAIDs (knee)
  • Oral NSAIDs
  • Intraarticular glucocorticoid
23
Q

OA Treatment overview:

Conditionally recommended pharm includes:

A
  • Acetaminophen
  • Tramadol
  • Duloxetine
  • Chrondroitin
  • Topical capsaicin
24
Q

OA Treatment overview:

Strongly against and conditionally against the following pharm:

A

Strongly against:

- Glucosamine
- Chrondroitin (knee and hip)
- Intraarticular hyaluronic acid (hip)

- Bisphosphonates
- csDMARDs
- bDMARDs

Conditionally against:

  • Chrondroitin (hand)
  • Intraarticular hyaluronic acid (hand and knee)
  • Topical capsaicin
  • Colchicine
  • Non-tramadol strong opioids
  • Fish oil
  • Vit D
25
Q

[Non-pharmaco for OA]

What are the mainstay treatment for OA?

These are all 1st line

A
  1. Exercise
  • Goal: reduce pain and improve/preserve physical function, strengthen function and prevent deterioration, improve QoL
  • 30min, 3x per week
  • Types: strengthening, neuromuscular, low-impact aerobic such as walking, aquatic aerobics, tai chi to improve balance
  • Consider physiotherapy as well - supervised exercise has better outcomes
  • Consider: splints/braces
  • Explain to pt: joint pain may increase when they start, but doing regularly and consistently and reduce pain and increasing functioning and QoL in the long-term
  1. Weight management
  • Goal: reduce load/stress on weight-bearing joints and adipokines-related inflammation, thereby reducing pain, improve QoL and physical function
  • Explain to pt: the more weight lost, the greater the improvements in QoL, physical function, and reduction in pain
  1. Information and support
  • Counsel pt on pairing analgesic to support exercise, however analgesic for short-term; thus exercise + weight management are key
  1. May also use RICE
26
Q

[Non-pharmaco for OA]

Why is surgical intervention not 1st line?

A

Lifespan of ~10y, delay until patient really needs it

27
Q

[Non-pharmaco for OA]

Who to consider for surgical intervention

A

Total joint arthroplasty (replacement)

  • Individuals whose QoL substantially affected (due to pain, stiffness, reduced function, progressive joint deformity)
  • Individuals in whom non-surgical treatment was not effective
28
Q

[Non-pharmaco for OA]

For successful outcome of surgical intervention…

A

Postoperative rehabilitation is essential

  • Physiotherapy + Painkiller
29
Q

[Non-pharmaco for OA]

Contraindications to surgical interventions

A
  • Active infection (preoperative assessment: ESR, CRP, joint aspiration, MRI)
  • Chronic lower extremity ischemia
  • Skeletal immaturity

Do not exclude from surgical intervention: age, gender, smoking, comorbidities, overweight

30
Q

[Non-pharmaco for OA]

Others:

A
  • Physical therapy
  • Occupational therapy
  • Transcutaneous electrical nerve stimulation (TENS) to help muscle contract, reduce pain => strongly against
  • Cortisone injections
  • Lubrication injections
  • Realigning bones (e.g., remove wedge from tibia to align knee joint)
  • Joint replacement
31
Q

[Pharmaco for OA]

Indication for pharmaco in OA:

A

Facilitate and support maximum function and engagement with non-pharmacological treatment approaches + relief pain

32
Q

[Pharmaco for OA]

What is 1st line?

A

NSAIDs

Start with topical over oral as topical has least systemic exposure

33
Q

[Pharmaco for OA]

Dose initiation and treatment duration

A

Lowest effective dose for shortest possible duration

34
Q

[Pharmaco for OA]

Use of topical NSAIDs (hand/knee/hip)

A

Topical NSAIDs should be considered for OA at the knees

May not be feasible at the hands - e.g., due to frequent handwashing

Unlikely to benefit OA at hip - depth of joint beneath skin surface is too deep, will require IA corticosteroids

35
Q

[Pharmaco for OA]

Counseling points for oral NSAIDs

A
  • Potential GI, CVS, renal toxicity
  • Use lowest effective dose for shortest duration only when needed (PRN basis)
  • Consider PPI prophylaxis for GI ulcers with NSAID use
36
Q

[Pharmaco for OA] - Alternatives

What might be considered if pt is contraindicated to NSAIDs?

A

Conditionally recommended:

  • Oral paracetamol
  • Oral tramadol (25-50mg TDS for mod-severe pain; max 400mg/day)

Note: these are not anti-inflammatory

37
Q

[Pharmaco for OA] - Alternatives

When might intraarticular glucocorticoid injections be considered?

A

Strongly recommended:

Depot glucocorticoid suspension

  • Short-term pain relief (4-6 weeks), for mod-severe pain
  • Effect is short-lived: 6 weeks-few months
  • More for knee or hip; not in hand
  • Routine/regular use is not recommended; 3 injections per year
  • No evidence with long term use
38
Q

[Pharmaco for OA] - Alternatives

Contraindications for intraarticular glucocorticoid injections:

A
  • Periarticular infection
  • Septic arthritis
  • Periarticular
  • Joint instability
  • Juxtaarticular osteoporosis
39
Q

[Pharmaco for OA] - Alternatives

Duloxetine (SNRI):

A

Conditionally recommended:

Use: for mod-severe symptoms with contraindication/inadequate response to NSAIDs

SNRI SEs:

  • GI: Nausea, Vomiting, Diarrhea (5-HT3 agonism)
  • Sexual dysfunction (5-HT2 agonism)
  • Initial transient jitteriness (due to sudden incr in neurotransmitters)
  • Insomnia
  • Urinary hesitancy
40
Q

[Pharmaco for OA] - Alternatives

Topical Capsaicin:

A

Conditionally recommended:

Capsaicin is an agonist for TRPV1 receptor, an ion channel receptor on nociceptive nerve fibers in the skin

Topical administration causes ‘nociceptor defunctionalization’, initial enhanced stimulation of TRPV1-expressing cutaneous nociceptors causing pain, followed by pain relief mediated by a reduction in TRPV1-expressing nociceptive nerve ending

PATCH - do not use for >5 consecutive days
SEs - application site reaction (burning, erythema, pain)

41
Q

Follow-up and review

A
  • Patient initiated follow-up for most ppl with OA; advice pt when to seek medical attention if management not working (i.e., 7-10 days)
  • Consider planned follow-up if needed (e.g., the severity of symptoms or functional limiations, monitoring of treatment etc.)